EGR1 and B-cell chronic lymphocytic leukemia: Finally, as suggested by the experiments performed with conventional RT‐PCR (Fig. 3A), ibrutinib did not repress EGR1 and DUSP2 after CLL stimulation with both anti‐IgM and CD40L compared to DAPKi, indicating that DAPKi had a broader repressive effect than ibrutinib (Fig. 4E).